©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Unique Autoantibody Epitopes in an Immunodominant Region of Thyroid Peroxidase (*)

(Received for publication, October 20, 1995; and in revised form, December 21, 1995)

Patricia L. Arscott (1) Ronald J. Koenig (1) Michael M. Kaplan (1) Gary D. Glick (2) James R. Baker Jr. (1)(§)

From the  (1)Departments of Internal Medicine and (2)Chemistry, University of Michigan, Ann Arbor, Michigan 48109

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES

ABSTRACT

To define the autoantibody epitopes in amino acids 513-633 of thyroid peroxidase (TPO), a region frequently recognized in thyroiditis, cDNA sequences coding for peptide fragments of this region were amplified and ligated into pMalcRI and pGEX vectors for expression as recombinant fusion proteins. Western blots and enzyme-linked immunosorbent assay were then used to examine the reactivity in sera from 45 Hashimoto's and 47 Graves' disease patients. Two autoantibody epitopes within TPO amino acids 589-633 were identified; 16 of 35 patients reactive to TPO513-633 recognized the epitope of TPO592-613, while 6 patients recognized the epitope of TPO607-633. Eleven other patients with thyroiditis and two with Graves' disease recognized only the whole 589-633 fragment, and this response accounted for the Hashimoto's disease specificity. An amino acid sequence comparison of TPO592-613 with analogous regions of other peroxidase enzymes revealed significant differences in this area, and the substitution of even a single amino acid in one of the epitopes markedly decreased the binding affinity of autoantibodies. Additionally, the exclusive recognition by patients of only one of the epitopes within this region suggests a genetic restriction of the autoantibody response.


INTRODUCTION

Thyroid peroxidase (TPO) (^1)is an autoantigen that is recognized by autoantibodies from patients with either Hashimoto's thyroiditis or Graves' disease(1) . However, the basis of immune responses to this antigen in autoimmune thyroid disease (AITD) is not clear(2, 3) . Studies have indicated that TPO is a complex autoantigen having at least two conformational and several localized autoantibody epitopes(4, 5, 6) . Two TPO regions, amino acids 513-633 and 710-740, have been identified as containing autoantibody binding sites(6, 7) , and we have attempted to correlate autoantibodies to these regions with manifestations of AITD(8) . No difference was observed in the overall serologic response to either native or denatured TPO in Graves' disease and Hashimoto's thyroiditis(8) . However, autoantibodies against TPO amino acids 513-633 were identified more commonly in Hashimoto's thyroiditis patients than in Graves' disease patients(8) . This has focused our current studies on the antigenic characterization of this region of TPO.

The exact nature of the autoantibody epitope or epitopes in TPO amino acids 513-633 is not clear. The location and conformational dependence of epitopes in this region may be important because this area contains a cysteine which may be involved in intra- or interchain disulfide linkages in the TPO enzyme complex(9) . A histidine residue proposed to be involved in tethering the heme coenzyme is also located within this site, suggesting a role in enzymatic function(10) . This region of TPO shares significant structural homology with myeloperoxidase (11) and lactoperoxidase(12) , suggesting the possibility of antigenic cross-reactivity or molecular mimicry(13, 14) . This suggests that there may be unique structural and immunologic aspects to this area of TPO. Therefore, characterizing the antigenicity of this region may lead to an understanding of the potential role of this activity in disease pathogenesis(15) .

In order to better understand the antigenicity of this region, we employed recombinant fusion proteins and synthetic peptides to characterize the autoantibody epitopes within the region of TPO amino acids 513-633. The structural nature and specificity of these sites were clarified, and the associations with different forms of autoimmune thyroid disease were analyzed. The results suggest that the autoantibody responses to this region in patients with AITD are heterogeneous in nature and may be genetically restricted.


MATERIALS AND METHODS

Patient Sera

Serum from 45 patients with Hashimoto's disease, 47 patients with Graves' disease, and 34 age- and sex-matched normal controls were studied. The age of the patients ranged from 17 to 82 years. The Hashimoto's patients were diagnosed on the basis of anti-microsomal antibody titers greater than or equal to 1:400 by agglutination assay in the presence of either goiter or hypothyroidism. Graves' disease was diagnosed on the basis of clinical and biochemical evidence of hyperthyroidism (suppressed TSH with elevated T4), diffuse goiter, and an increased 24-h radioiodine uptake. None of the controls had clinical evidence or a history of thyroid disease.

Clinical Measurements

The thyroid functions tests (including FT4, FT3) were performed in a routine clinical laboratory, and the TSH levels were determined by a chemiluminescence immunoassay with a sensitivity of 0.05 milliunits/liter (Magic-Lite, Corning, Medfield, MA). Thyroglobulin and microsomal antibody titers were determined by agglutination assay (Ames Diagnostics, Ames, IA). Goiter size and the presence of ophthalmopathy were determined by one of the investigators (M. K.) who was unaware of the TPO reactivity of the subjects.

Construction of TPO Expression Plasmids Using PCR

Oligonucleotides were designed and used in various combinations as PCR primers to generate cDNAs coding for TPO fragments within the region of amino acids 513-633 (Fig. 1). The primers were designed so that the resulting PCR products contained an EcoRI recognition sequence at the 5` end, followed by the (in-frame) TPO coding sequence, a stop codon, and an XbaI recognition site at the 3` end. Plasmid DNA from pMalTPO513-633 developed from pMalcRI expression plasmid (New England Biolabs) containing (in-frame) the cDNA coding for TPO amino acids 513-633 (8) was used as a template (10-50 ng/amplification mixture) with 200 ng of the 5` and 3` primer, 0.8 mM mixed dNTP, 4 mM MgCl(2), 1.25 units of Taq DNA polymerase in 50 mM KCl, 10 mM Tris-HCl, pH 9.0 with 0.1% Triton X-100 (Promega) in a total volume of 50 µl. The reaction was run on a GeneAmp PCR System 9600 (Perkin-Elmer) using a two-step program of 94 °C for 10 s, then 60 °C for 15 s for 25 cycles, followed by a single incubation at 72 °C for 10 min, then chilled to 4 °C. The amplified product was phenol-extracted and precipitated, then digested with EcoRI and XbaI to create the 5` and 3` cut sites (respectively). The digested material was separated on an 8% nondenaturing polyacrylamide gel, and the appropriately sized band was excised and eluted. Each product was ligated into a pMalcRI expression plasmid that had been linearized with EcoRI and XbaI to create new pMalTPO plasmids. The resulting plasmids were used to transform Escherichia coli HB101, and ampicillin-resistant colonies were screened for the appropriate insert by PCR using a 5` primer complementary to a site within the vector (86 bases upstream of the EcoRI insertion site), with the 3` primer originally used to amplify the inserted fragment. The DNA sequence and reading frame of each new construct was confirmed by dideoxynucleotide sequencing spanning the 5` insertion site of the TPO cDNA sequence. Clones from each construct were grown and induced to produce fusion protein and then purified as described(7) . Each protein was then characterized by Western blotting using a monoclonal antibody to detect the MBP fusion proteins and human sera previously found to be reactive to the 513-633 fragment, to detect specific reactivity to the TPO fragment .


Figure 1: Recombinant proteins were used to map a TPO epitope within the region of amino acids 513-633. The DNA coding sequence for TPO amino acids 589-633 and the primers used in various PCR amplifications is shown. The PCR primers were constructed to produce 5` EcoRI and 3` XbaI restriction sites (underlined) for ligation of the PCR product into the pMalcRI vector. Primer sequence complementary to TPO sequence (in bold) is spaced in triplets to show the reading frame after insertion into the vector. A stop codon in-frame at the 3` end of the PCR product was also engineered into the 3` primer to ensure the appropriate termination of the fusion protein.



Construction of TPO589-613 Containing Substituted Amino Acids

Oligonucleotides were synthesized to correspond to TPO589-613 cDNA sequence that altered glutamic acid residues at positions 593 and 596 in TPO. Two sense strand oligonucleotides were designed for amino acids 589-604. One of the strands coded for serine and glycine residues at position 593 and 596, respectively, corresponding to the amino acids at the homologous positions in lactoperoxidase (LPO) (5`-AATTCCCAGGTTACAATTCGTGGAGGGGGTTCTGCGGCCTGCCTCGCCTG GAG) (Fig. 3). The other sense strand oligonucleotide coded for alanine at amino acid 593 and arginine at amino acid 596, corresponding to the amino acids in myeloperoxidase (MPO) at comparable sites (5`-AATTCCCAGGTTACAATGCGTGGAGGAGGTTCTGCGGCCTGCCTCGCCTGGAG) (Fig. 3). Both sequences maintained the TPO coding sequence for all other residues within the 589-613 region. A common antisense strand was synthesized to match the TPO cDNA sequence for amino acids 599-613 (5`-CTAGACTAGATGGCTGTGCTCAGGTCAGCGGGGGTCTCCAGGCGAGGCAGGCC) with a stop codon at the 5` end. Both strands contained an overlapping complementary region of 18 bases and, after phosphorylation, were annealed and ligated with pMalcRI that had been linearized with EcoRI and XbaI. Each ligation reaction was treated with Klenow reagent to fill in the single-stranded gaps. These new plasmids were used to transform E. coli HB101, then colonies were selected and sequenced to confirm the substitutions and reading frame of the final construct.


Figure 3: The amino acid sequence for TPO592-613 is compared to the analogous sequences from MPO and LPO. Substitutions from the TPO sequence are indicated. The glutamic acids at positions 593 and 596 of TPO are underlined to identify the substitutions made in several of the TPO fusion proteins used to test binding specificity. The amino acids after position 601 (in TPO) show great heterogeneity between the three proteins.



Construction and Expression of TPO cDNA in pGEX Vector

To ensure that the binding associated with the recombinant TPO fragments was not altered by the presence of the bacterial fusion protein component or the intervening sequence, the constructs produced in the pMal vector were also produced in a pGEX-3T expression vector (16) . A single base was added to the multiple cloning region of pGEX-3T, before the EcoRI site (creating a plasmid designated as pGEX-ML), to alter the reading frame of cDNA inserts to match that in pMalcRI. The TPO cDNAs were cut from the corresponding pMalTPO plasmids using EcoRI and SalI, purified on an 8% nondenaturing polyacrylamide gel, then ligated into pGEX-ML vector that had been linearized with EcoRI and SalI. The pGEX-TPO constructs were then used to transform E. coli HB101 and selected by ampicillin resistance. Subsequent dideoxy DNA sequencing of both strands of the plasmid confirmed the TPO coding sequence. Bacteria containing the correct pGEX-TPO construct were then grown and induced to express protein, and the soluble proteins were isolated and affinity-purified as described(16) .

SDS-Polyacrylamide Gel Electrophoresis and Western Blots

TPO fusion proteins were diluted in 0.125 M Tris, pH 6.8, with 4% SDS, 20% glycerol, and 10% beta-mercaptoethanol and boiled for 3 min before electrophoresis. Approximately 50 µg of total protein was loaded into individual wells and electrophoresed through a 10% SDS-polyacrylamide gel. After electrophoresis, proteins were electrotransferred to nitrocellulose membranes, which were then blocked with 3% bovine serum albumin in PBS-A for 2 h at 27 °C. Western blots were performed using patient sera diluted 1:400 in 1% bovine serum albumin/PBS-A. Controls included a monoclonal antibody to MBP (University of Michigan Hybridoma Core Facility) to identify the bands corresponding to MBP fusion proteins, as well as sera from several patients with antibody to TPO513-633(8) . GST-TPO fusion proteins were also confirmed by Western blot using a polyclonal mouse serum to GST (produced in our core facility by immunization with the GST portion of the fusion protein). Control MBP and GST proteins, produced from bacteria transformed with vector without TPO insert, were also electrophoresed and blotted as control antigens.

TPO Fragment ELISA

A MAP peptide (17) consisting of TPO amino acids 592-613 coupled to a polylysine backbone was synthesized (University of Michigan Protein Core Facility). The peptide was first solubilized in dimethyl sulfoxide, then diluted to 20 µg/ml in 0.05 M sodium carbonate, pH 9.6, buffer with 0.02% sodium azide. Immulon-2 ELISA plates (Dynatech) were coated by adding 100 µl per well and incubating overnight at 4 °C. The wells were then washed with PBS-A with 0.05% Tween-20 and blocked with 150 µl per well of 10% nonfat dry milk in PBS-A and incubated for 1 h at 27 °C. After washing the wells, patient serum was diluted in PBS-A containing 10% nonfat dry milk and added in serial dilutions from 1:200-1:25,600 at 100 µl per well and incubated for 2 h at 37 °C. The wells again were washed, and then incubated for 1 h at 37 °C with 100 µl per well of alkaline phosphatase-conjugated goat anti-human IgG (Jackson Laboratories, West Grove, PA) diluted at 1:5000 in PBS-A. 100 µl per well of p-nitrophenyl phosphate substrate (104-Phosphatase substrate, Sigma, at 1 mg/ml in 0.05 M sodium carbonate, pH 9.8, buffer with 1 mM magnesium chloride) was added to each well, and absorbance was measured at 405 nM. A positive patient serum was also diluted from 1:200-1:25,600 and included as an internal control on each plate, providing a standard for comparison. ELISA using GST fusion proteins was also performed using the sequences TPO589-633 or TPO607-633 to coat plates at 10 µg/ml. Serum reactivity was assayed as described with the peptide. To block possible antibody reactivity to the GST portion of the fusion protein, sera were preincubated with 0.1 mg/ml purified recombinant GST protein for 1 h at 27 °C before being added to the wells.

Inhibition of ELISA Using TPO Fusion Proteins

Binding of serum antibodies to the TPO592-613 peptide by ELISA was inhibited by the various TPO fusion proteins containing amino acids from within the 513-633 region. Serum from eight patients positive to the TPO592-613 epitope was diluted with 10% milk/PBS-A to 1:400 or 1:1000. Inhibitor concentrations from 10M to 10M were preincubated with the diluted serum for 2 h at 27 °C. The mixture was then added to the TPO592-613 peptide-coated ELISA plate, and the procedure was completed as described above.

Computer Modeling of Epitope Structure

Computational molecular modeling was conducted on a Silicon Graphics 360GTX computer running the ISIGHT/DISCOVER software package. Epitopes were constructed in a turn geometry as suggested by the mapping experiments, and conformational energy was minimized using a conjugate-gradient algorithm and the AMBER united atom force field to a first derivative root mean square derivative < 0.1 Å^2. Structure predictions for the epitopes used the Karplus neural net algorithm as implemented in the PROTEIN PREDICTOR software package(18) . The results from the analysis were compared with predictions using the Kyle-Doolittle and Chothia routines to ensure appropriateness(19) .

Analysis of Amino Acid Sequence Similarities

Amino acid sequence analysis for the specific epitopes within this region was conducted as a BLASTA search through the National Library of Medicine (20) .


RESULTS

Mapping of TPO513-633 Fragment Epitope Using Truncated Fusion Proteins

PCR amplification of the TPO cDNA and ligation into pMalcRI produced a number of different fusion proteins with sequences corresponding to TPO amino acids within the region 513-633, as depicted in Fig. 1. These MBP-TPO fusion proteins were initially screened by Western blots for reactivity using sera from Hashimoto's patients with high titer antibody to amino acids 513-633 (8) . Positive sera were diluted to 1:400 and did not demonstrate binding to the MBP-LacZ control protein at this dilution. Western blots of fusion proteins produced by the different constructs, incubated with a monoclonal antibody to the MBP portion of the fusion protein (Fig. 2, A and C, left lanes), document all of the MBP-TPO fusion proteins and indicate that equivalent amounts of all of the protein are present in both transfers (also demonstrated by protein stain of gel, Fig. 2B). Blots with a Hashimoto's disease serum (Fig. 2, A and C, right lanes) demonstrate positive and negative binding where the patient's serum recognizes the fusion protein band from pMalTPO592-613 but not from pMalTPO589-607. All of the different sized TPO fusion proteins were similarly tested for reactivity using patient sera and showed definitive positive or negative binding using this technique. Employing the fragments outlined in Fig. 1, three different epitopes were suggested as being present in this region of TPO; one epitope corresponding to the amino acids from 592 to 613 showed reactivity with the highest number of patients and shared significant sequence homology with analogous regions of MPO and LPO (Fig. 3).


Figure 2: Patient reactivity to specific recombinant TPO fragments was determined by Western blot analysis of bacterial lysates containing MBP-TPO fusion proteins. Western blots were performed using an anti-TPO513-633 reactive Hashimoto's patient serum at 1:400 (right lanes) to identify TPO-specific reactivity or an anti-MBP monoclonal antibody (MAb) to identify the presence of MBP fusion proteins (left lanes). A, the Hashimoto's patient serum does not bind to MBP-TPO589-607 (lane 1, arrow) but is reactive with the MBP-TPO589-613 (lane 2, 40-kDa band) and the MBP-TPO513-633 (lane 3, 56-kDa band) control proteins. The anti-MBP monoclonal antibody blot as well as the Coomassie Blue-stained gel (B) demonstrate that large amounts of all of the fusion proteins are present. C, the patient serum is reactive with MBP-TPO592-613 (lane 1, arrow) and MBP-TPO589-613 control proteins (lanes 2 and 3). D, TPO fragments were also expressed as GST fusion proteins using the pGEX vector. Some GST-TPO fusion proteins are shown on a gel stained with Coomassie Blue (bottom section, 28-31 kDa), and TPO reactivity is confirmed by Western blot using the same patient serum (top section).



To determine whether patients reacted to more than a single epitope within the larger region of amino acids 513-633, lysates of the various MBP-TPO fusion proteins were used to inhibit binding to MBP-TPO513-633 on Western blot (Fig. 4). Serum from 5 positive patients and the anti-MBP monoclonal antibody were preincubated with either 1% bovine serum albumin (``+'' strips), MBP-TPO592-613 lysate (A strips), MBP-TPO607-633 lysate (C strips), or purified MBP-TPO513-633 (B strips), then incubated with strips from a Western blot of MBP-TPO513-633. Control strips incubated with anti-MBP monoclonal antibody identify the 56-kDa MBP-TPO513-633 fusion protein and confirm that preincubation with the other MBP fusion proteins would inhibit antibody binding. Sixteen patients in all demonstrated binding to the TPO592-613 fragment and had the reactivity to the TPO513-633 fusion protein inhibited by preincubation with this fragment (``A'' strips, demonstrated by the blots from patients H1, H2, and G1). Six other patients had binding to TPO513-633 inhibited only by preincubation with the MBP-TPO607-633 fusion protein (C strips, demonstrated by the blot from patient H4), while in 13 other patients, binding to the TPO513-633 fusion protein was not inhibited by either or both smaller fusion proteins (demonstrated by the blot from patient H3). GST-TPO fusion proteins containing the same TPO amino acid sequences (Fig. 2D) demonstrated identical patterns of reactivity to what was observed with the MBP-TPO fusion proteins, indicating that the fusion protein or linker portion of the construct did not alter the binding to this region of TPO and was not involved in the inhibition. The ability of autoantibodies against TPO513-633 to bind whole native TPO was assessed by Western blot using affinity-purified antibody. Affinity-purified antibody to 513-633 recognized only the reduced form of native TPO (data not shown).


Figure 4: Inhibition of patient serum binding to MBP-TPO513-633 by preincubation with different MBP-TPO fusion proteins indicates the presence of an epitope in amino acids 592-633 other than either 592-613 or 607-633. Western blots are shown using serum from four Hashimoto's thyroiditis patients and one Graves' disease patient, as well as a positive control blot made with an anti-MBP monoclonal antibody. Each serum was preincubated with 0.2 mg of either MBP-TPO592-613 lysate (A strips), MBP-TPO513-633 (B strips), or MBP-TPO607-633 lysate (C strips) for 1 h at 37 °C. A control strip, preincubated in 1% bovine serum albumin (+ lanes), shows the uninhibited binding of each patient to the MBP-TPO513-633 band on the blot. Some patients demonstrated complete inhibition with either the MBP-TPO592-613 (H1, H2) or the MBP-TPO607-633 (H4) fusion protein. However, binding of serum from another patient is only partially inhibited (G1) or not inhibited (H3) by the MBP-TPO592-613 and the MBP-TPO607-633 proteins.



Patient Reactivity to Epitopes within TPO Amino Acids 513-633

To examine the frequency of autoantibodies to these various regions in patients with Graves' disease and Hashimoto's thyroiditis, reactivity to either TPO592-613, TPO607-633, or TPO589-633 fragments was measured by ELISA and Western blot (Table 1). Patient reactivity to TPO592-613 also was measured by ELISA using a MAP peptide corresponding to this sequence. Patient sera were analyzed at serial dilutions from 1:200-1:25,600; representative dilution curves for 6 positive and 5 negative patients are presented in Fig. 5. Absorbances from either 1:400 or 1:800 serum dilutions were compared to the dilution curve for the positive control, and relative value units were calculated for each patient. Positive patients were identified by both the relative units and the antibody titer, the latter being defined as the lowest serum dilution maintaining activity above background. No normal serum demonstrated binding to this peptide (0 of 30). 8 of 45 Hashimoto's thyroiditis patients and 9 of 47 Graves' disease patients were positive to the TPO592-613 epitope. Positive antibody titers ranged from 1:200 to 1:25,600; however, there was no correlation between these values and the overall titers of microsomal antibodies as determined by agglutination assay. Among the reactive Hashimoto's thyroiditis patients, the average titer to TPO592-613 was 1:9,450 while the reactive Graves' disease patients had an average titer of 1:7,475. (Median titers for Graves' disease patients were 1:1, 600 and 1:3, 200 for Hashimoto's thyroiditis patients).




Figure 5: A MAP peptide ELISA was used to quantify autoantibody responses to TPO amino acids 592-613. Dilution curves of serum from six positive and five negative patients are shown as examples. Serum was serially diluted 1:200-1:25,600 and added to ELISA plates coated with 25 µg/ml MAP-TPO592-613. Titers for positive patients ranged from 1:200 to 1:25,600, while the negative patients (those with absorbance less than 0.2 at 1:200 dilution) show no reactivity at any sera dilution. The shaded line indicates the 95% confidence interval of normal sera.



ELISA employing GST fusion proteins containing TPO589-633 or TPO607-633 were used to examine the patients who reacted with other epitopes within TPO513-633. 4 of 31 Hashimoto's thyroiditis patients and 2 of 25 Graves' disease patients tested were positive to the 607-633 epitope. Thirteen sera that bound TPO513-633 also reacted with the whole 589-633 region, but not to either the 592-613 or the 607-633 epitope, reinforcing the finding of the inhibition study that this whole fragment appeared to be a single epitope in some patients. Patients reactive to TPO589-633 but not to TPO592-613 also did not recognize TPO589-613. 34 of the 35 patients with autoantibodies reactive to the TPO589-633 region exclusively recognized one of the defined epitopes (Table 1).

Affinity of Autoantibodies to TPO592-613

Competitive inhibition of serum reactivity to the TPO592-613 peptide ELISA using different concentrations of TPO fusion proteins was employed to provide a relative estimation of antibody affinity. Affinity was defined as the concentration of inhibitor reducing ELISA reactivity of the serum by 50%. Overlapping GST-TPO fusion proteins including the sequence of amino acids 592-613 were used to inhibit serum from eight patients with high titer antibody to this epitope. Fig. 6shows representative ELISA inhibition curves from a positive patient. Preincubation of positive serum with the GST fusion protein containing TPO513-633 inhibited binding to the 592-613 peptide by 50% at about 4 times 10M, TPO589-633 inhibited at about 8 times 10M, and the TPO589-613 construct at 2 times 10M. Inhibition with the TPO592-613 construct and the MAP592-613 peptide demonstrated an affinity of about 1 times 10M in this assay. The fusion protein GST-TPO607-633 was included as a negative control in this assay and did not inhibit binding of any of the sera reactive to TPO592-613. Similar results were obtained when inhibitions were performed using the MBP-TPO fusion proteins, indicating that the fusion and linker portions of the protein do not alter autoantibody binding. The affinity of binding to TPO592-613 was affected by the size of the TPO construct, especially at the amino end of the epitope. This is shown with TPO589-613, which demonstrates nearly 10-fold greater autoantibody affinity than TPO592-613 (Fig. 6). Five of the eight patients evaluated in this manner demonstrated high affinity binding to the TPO592-613 epitope requiring concentrations of greater than 1 times 10M to displace autoantibody binding, while the three other patients demonstrated approximately 50-fold lower affinity (Fig. 6, inset).


Figure 6: Comparative affinity of autoantibodies for the TPO 592-613 epitope was determined by the inhibition of serum binding in the TPO592-613 peptide ELISA. Sera from positive patients were preincubated with decreasing concentrations of GST-TPO fusion proteins containing the sequence of amino acids 592-613 or 607-633 as a negative control. The preincubated serum was then used in the TPO592-613 peptide ELISA. Binding in the ELISA was inhibited completely by 10M or 10M of all constructs containing amino acids 592-613. The larger constructs, containing 589-633, demonstrated a higher affinity of about 10 about 10-80 times greater than either of the smaller constructs of 589-613 or 592-613. The 607-633 fusion protein served as a control and demonstrated minimal inhibition capability (<15%) at 10M which disappeared completely at 10M. Similar results were obtained using MBP-fusion proteins (not shown). The relative affinities for 8 patients (inset graph) show high affinity binding in 5 of these patients.



Alterations in Autoantibody Binding Induced by Amino Acid Substitutions within 592-613

The amino acid sequence of this epitope was compared to analogous sequences from two closely related proteins, lactoperoxidase (LPO) and myeloperoxidase (MPO) (Fig. 3). The two glutamic acid residues of the TPO epitope at amino acids 593 and 596 seemed important as these residues are highly charged and are not conserved in the other two proteins. Constructs were constructed substituting the glutamic acid residues at positions 593 and 596 in TPO to match the corresponding amino acids in either LPO or MPO. An additional construct of TPO589-633 (TPO596-Gly) contained a single substitution of the glutamic acid at 596 to glycine. These constructs were expressed as GST-TPO fusion proteins and used at concentrations ranging from 10M to 10M to inhibit the binding of autoantibodies to the 592-613 peptide ELISA (Fig. 7). Substitutions of 593-alanine and 596-arginine (as in MPO) in this epitope resulted in the complete loss of binding inhibition in all patients reactive with TPO592-613. Substitutions of 593-serine and 596-glycine (as in LPO), and the construct containing the single 596-glycine substitution each increased the amount of fusion protein required to inhibit binding to 592-613 by 10-100-fold. Although many TPO592-613 reactive patients demonstrated some reactivity with the 593-serine- and 596-glycine-substituted (LPO) constructs in this assay, the apparent affinity was in all cases less than what was seen with the TPO construct (ranging from no binding to 4 times 10M).


Figure 7: The specificity of autoantibody binding to TPO592-613 was demonstrated by the inhibition of the TPO592-613 peptide ELISA with GST-TPO fusion proteins containing altered amino acids within the region of amino acids 589-613. Constructs were made which replaced the glutamic acids at amino acids 593 and 596 of TPO with serine at 593 and glycine at 596 or with alanine at 593 and arginine at 596. An additional construct contained the single substitution of glycine for glutamic acid at amino acid 596 in TPO589-633. The mutated TPO fusion proteins were used to inhibit positive serum binding in the TPO592-513 peptide ELISA and were compared to inhibition with the native sequences. None of the altered constructs demonstrated 50% inhibition of binding at concentrations nearly 100 times greater than that which achieved this level of inhibition in the native constructs. Similar results were obtained using MBP-fusion proteins (not shown).



Structural Modeling of the Region

Modeling of the region from amino acids 592 to 613 did not demonstrate secondary structure of either beta sheet or alpha helical configuration. Instead, the region appeared to be a semirigid loop defined by proline residues at 601 and 606 (Fig. 8). The cysteine at position 598, near the ``tip'' of the loop, appears to be available for disulfide linkages with other portions of the molecule. The charged residues, glutamic acids at positions 593 and 596 and the arginine at positions 595 and 602, possibly stabilize the loop via charge interaction.


Figure 8: Computer modeling of the 592-613 epitope of TPO. Note the tight loop without tertiary sheet or helical structure. The two glutamic acids, substituted in some of the fusion proteins, are shown with space-filling balls.



Clinical Associations

Although TPO592-613 autoantibodies appear in a large number (15 of 35) of TPO513-633 reactive patients, there was no apparent relationship between Hashimoto's thyroiditis and autoantibody binding. As seen in Table 1, differences in binding in Hashimoto's and Graves' disease patients seem to be accounted for by antibodies reactive only with the whole region of amino acids 589-633; 11 thyroiditis patients (24%) reacted to this region as compared to only 2 Graves' disease patients. There was no correlation between overall TPO reactivity in patients reactive to any of these epitopes. Anti-thyroglobulin antibodies were found in 85% of the patients studied and also did not correlate with reactivity to any localized epitope.

No correlation between reactivity to 592-613 and measures of thyroid function such as FT4, FT3, TSH levels, iodine uptake, or presence of goiter was observed for either Hashimoto's thyroiditis or Graves' disease patients. However, among the thyroiditis patients, hypothyroidism was significantly more common in those that recognized TPO592-613 (7 of 8, 88%) as compared to individuals recognizing the whole 589-633 epitope (5/11, 45%, p < 0.05).


DISCUSSION

These studies identify three autoantibody epitopes in the region defined by TPO amino acids 589-633; two containing only portions of the amino acid sequence, as well as the whole region which was also recognized as a single epitope. Computer modeling of this area revealed neither alpha helix nor beta sheet structure, but instead the region appears to be a loop held in conformation by prolines at positions 601 and 606. A cysteine at residue 598, just before the two prolines and near the tip of the loop, suggests that the region may be involved in disulfide linkages within the TPO molecule. This is in accordance with the structure of TPO, which is currently believed to be a disulfide-linked dimer of two 105-kDa chains containing both intrachain and interchain disulfide bonds(9, 10, 21, 22) . Autoantibodies against the 589-633 region are unable to bind to TPO unless it is reduced, indicating that the epitopes are inaccessible in the native molecule. Together, this information indicates that the epitopes within the 589-633 region of TPO may be neotopes, or sites that are not normally exposed to the immune system(23) .

The serologic response to this particular region of TPO provides a number of insights into immune mechanisms underlying autoimmune thyroid disease. The autoantibody response to TPO is heterogeneous with different individuals recognizing unique epitopes. This has also been observed with the immune response to conformational epitopes in TPO, and it has been hypothesized to occur due to differences in immunoglobulin variable-region genes that might allow interaction with specific autoantibody binding sites(24) . In contrast to the response to conformational epitopes, the immune response to epitopes in the 589-633 region is restricted to a single site in almost all the individuals examined. The basis of this mutually exclusive epitope recognition is not clear, but it is possible that several of the binding sites within this region are initially recognized, and the immune response then evolves to a single, strongest epitope that excludes the other responses. This possibility is difficult to evaluate since the patients we investigated had mature autoimmune disease and had already evolved their autoantibody response. This restricted recognition could also be based on a genetic restriction, not the result of evolutionary changes in the immune response, and the evaluation of TPO epitope recognition in relatives of these patients may help to clarify this issue.

While portions of the 589-633 region demonstrate substantial conservation in amino acid sequence with analogous areas of other peroxidase enzymes, including myeloperoxidase and lactoperoxidase(11, 12) , areas of the amino acid sequences of the autoantibody epitopes within this region appear to be unique to TPO. Particularly, the charged residues and the prolines are unique to TPO and appear necessary to maintain antigenicity. Substitution of one of the charged amino acids with the corresponding sequence of LPO or MPO markedly decreases antibody affinity for the most dominant epitope in this region. This suggests that TPO autoantibodies develop from recognition of the autoantigen and not molecular mimicry from LPO or other antigens. However, a cross-reactive response to another antigen, such as LPO, that has subsequently affinity matured specifically to the autoantigen, cannot be excluded entirely since these patients have well-established autoimmune disease.

The importance of antibodies binding to epitopes within the 589-633 region in the diagnosis and treatment of AITD is of interest. The titer of antibodies directed against this particular region of TPO varies between different individuals and does not correlate with the overall anti-TPO titer. As a result, some patients have high titer antibody against this region but relatively modest titers of anti-TPO antibodies in conventional assays. This has the practical implication that anti-TPO titers in some patients may be underestimated with serologic assays that measure antibodies against native TPO. The mechanisms underlying the recognition of this site in AITD is difficult to ascertain. It is possible that these epitopes are recognized only after inflammation has disrupted thyroid follicular cells and released unfolded or reduced TPO, a form of epitope spreading. Recognition of the whole region, which is restricted to Hashimoto's disease patients, would seem likely to be the result of this process. However, the presence of autoantibodies against the local epitopes did not correlate with overall anti-TPO titers, a putative marker of glandular inflammation and release of TPO. This makes it less likely that the response to these epitope is based purely on this process. The presence of antibodies to the 592-613 epitope in patients with Graves' disease, which is not associated with extensive thyroid follicular cell disruption, would also seem to argue against this. However, this latter finding might be explained by an overlap syndrome, where thyroiditis and Graves' disease exist concurrently. Prospective studies screening for TPO epitope autoantibodies in Graves' disease may therefore identify individuals who have concurrent thyroiditis and might not need thyroid ablative therapy.

Other autoimmune diseases have identified heterogeneous responses to autoantigens, particularly in inflammatory processes. The autoantibody response to the acetylcholine receptor in myasthenia gravis is similarly diverse, with the recognition of both localized and conformational epitopes on the alpha chain of this protein(25) . The recognition of glutamic acid decarboxylase in insulin-dependent diabetes mellitus is also heterogeneous with recognition of both localized and conformational binding sites (26) . It has been difficult in both of these situations to associate any particular manifestation of the disease with variations in autoantibody epitope recognition, so the lack of an association in this case is not surprising. Graves' disease has been suggested to be associated with several types of autoantibodies to the TSH receptor protein(27) . However, responses to particular epitopes in the TSH receptor have not been entirely characterized(28) , and mutually exclusive epitope recognition, in a manner similar to the response against the 589-633 region of TPO, has not been described. Thus, the findings of the present work on TPO in AITD support and extend what has been observed in other autoimmune diseases.

In conclusion, these studies demonstrate conclusively that the autoimmune response to TPO in autoimmune thyroid disease is heterogeneous and appears restricted in most patients and indicate that the initial events of TPO recognition involve the autoantigen itself. However, multiple factors are likely to be involved in initiating the autoimmune response in thyroiditis and Graves' disease, and some of these may be related to environmental antigens. These variables, together with the patient's own genetic background, might best account for the heterogeneity in immune responses that are seen in this protein in these diseases. Monitoring the response to the epitopes of TPO in the 589-633 area over time in patients with autoimmune thyroid diseases may clarify the evolution of the autoantibody response in these disorders and provide a better understanding of how the immune response to this protein evolves and contributes to thyroid disease pathogenesis.


FOOTNOTES

*
This work was supported by NIAID, National Institutes of Health Grant RO1 AI 37141-01. Core support was obtained from Grant P60 DK20572-16. This work was presented in abstract form at the National Meeting of the American Federation of Clinical Research. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom all correspondence should be addressed: Dept. of Internal Medicine and Pathology, 1150 W. Medical Center Dr., 1520 MSRB I, University of Michigan Medical School, Ann Arbor, MI 48109-0666. Tel.: 313-747-2777; Fax: 313-936-2990.

(^1)
The abbreviations used are: TPO, thyroid peroxidase; AITD, autoimmune thyroid disease; LPO, lactoperoxidase; MPO, myeloperoxidase; MBP, maltose-binding protein; GST, glutathione S-transferase; MAP, multiple antigenic peptide; PBS-A, phosphate-buffered saline with 0.02% sodium azide; TSH, thyroid-stimulating hormone; PCR, polymerase chain reaction; ELISA, enzyme-linked immunosorbent assay.


REFERENCES

  1. Weetman, A. P. (1990) Clin. Exp. Immunol. 80, 1-3 [Medline] [Order article via Infotrieve]
  2. McLachlan, S. M., and Rapoport, B. (1992) Endocr. Rev. 13, 192-206 [Medline] [Order article via Infotrieve]
  3. Rapoport, B. (1991) Annu. Rev. Med. 42, 91-96 [CrossRef][Medline] [Order article via Infotrieve]
  4. Portolano, S., Chazenbalk, G. D., Seto, P., Hutchison, J. S., Rapoport, B., and McLachlan, S. M. (1992) J. Clin. Invest. 90, 720-726 [Medline] [Order article via Infotrieve]
  5. Libert, F., Ludgate, M., Dinsart, C., and Vassart, G. (1991) J. Clin. Endocrinol. Metab. 73, 857-860 [Abstract]
  6. Banga, J. P., Barnett, P. S., Ewins, D. L., Page, M. J., and McGregor, A. M. (1990) Autoimmunity 6, 257-268 [Medline] [Order article via Infotrieve]
  7. Maastricht, J., Koenig, R. J., Kaplan, M. M., Arscott, P., Thompson, N., and Baker, J. R., Jr. (1992) J. Clin. Endocrinol. Metab. 75, 121-126 [Abstract]
  8. Bermann, M., Magee, M., Koenig, R. J., Kaplan, M. M., Arscott, P., Maastricht, J., Johnson, J., and Baker, J. R., Jr. (1993) J. Clin. Endocrinol. Metab. 77, 1098-1101 [Abstract]
  9. Baker, J. R., Jr., Arscott, P. A., and Johnson, J. (1994) Thyroid 4, 173-178 [Medline] [Order article via Infotrieve]
  10. Kimura, S., and Ikeda-Saito, M. (1988) Proteins 3, 113-120 [Medline] [Order article via Infotrieve]
  11. Kimura, S., Hong, Y. S., Kotani, T., Ohtaki, S., and Kikkawa, F. (1989) Biochemistry 28, 4481-4489 [Medline] [Order article via Infotrieve]
  12. Dull, T. J., Uyeda, C., Strosberg, A. D., Nedwin, G., and Seilhamer, J. J. (1990) DNA Cell Biol. 9, 499-509 [Medline] [Order article via Infotrieve]
  13. Oldstone, M. B. (1987) Cell 50, 819-820 [Medline] [Order article via Infotrieve]
  14. Mims, C. A. (1985) Br. Med. Bull. 41, 63-65 [Medline] [Order article via Infotrieve]
  15. Venables, P. J. W. (1993) Clin. Exp. Immunol. 94, 225-226 [Medline] [Order article via Infotrieve]
  16. Frorath, B., Abney, C. C., Berthold, H., Scanarini, M., and Northemann, W. (1992) BioTechniques 12, 558-563 [Medline] [Order article via Infotrieve]
  17. Posnett, D. N., and Tam, J. P. (1989) Methods Enzymol. 178, 739-746 [Medline] [Order article via Infotrieve]
  18. Hopp, T. P., and Woods, K. R. (1981) Proc. Natl. Acad. Sci. U. S. A. 78, 3824-3828 [Abstract]
  19. Chou, P. Y., and Fasman, G. D. (1978) Annu. Rev. Biochem. 47, 251-276 [CrossRef][Medline] [Order article via Infotrieve]
  20. Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. P. (1990) J. Mol. Biol. 215, 403-410 [CrossRef][Medline] [Order article via Infotrieve]
  21. Taurog, A., Dorris, M. L., Yokoyama, N., and Slaughter, C. (1990) Arch. Biochem. Biophys. 278, 333-341 [Medline] [Order article via Infotrieve]
  22. Banga, J. P., Mahadevan, D., Barton, G. J., Sutton, B. J., Saldanha, J. W., Odell, E., and Gregor, A. M. (1990) FEBS Lett. 266, 133-41 [CrossRef][Medline] [Order article via Infotrieve]
  23. Laver, W. G., Air, G. M., Webster, R. G., and Smith-Gill, S. J. (1990) Cell 61, 553-556 [Medline] [Order article via Infotrieve]
  24. Chazenbalk, G. D., Portolano, S., Russo, D., Hutchison, J. S., Rapoport, B., and McLachlan, S. (1993) J. Clin. Invest. 92, 62-74 [Medline] [Order article via Infotrieve]
  25. Manfredi, A. A., Protti, M. P., Bellone, M., Moiola, L., and Conti-Tronconi, B. M. (1992) J. Lab. Clin. Med. 120, 13-21 [Medline] [Order article via Infotrieve]
  26. Baekkeskov, S., Aanstoot, H. J., Fu, Q., Jaffe, M., Kim, J., Quan, J., Richter, W., and Shi, Y. (1993) Autoimmunity 15, 24-26 [Medline] [Order article via Infotrieve]
  27. Kosugi, S., Ban, T., Akamizu, T., and Kohn, L. D. (1992) Mol. Endocrinol. 6, 168-180 [Abstract]
  28. Baker, J. R., Jr. (1993) J. Clin. Endocrinol. Metab. 77, 16-18 [Medline] [Order article via Infotrieve]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.